8-K
Vicarious Surgical Inc. (RBOT)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): October 13, 2022
VICARIOUS
SURGICAL INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-39384 | 87-2678169 |
|---|---|---|
| (State or other jurisdiction<br> <br><br>of incorporation) | (Commission File Number) | (IRS<br> Employer<br><br> <br>Identification<br> No.) |
| 78 Fourth Avenue | ||
| --- | --- | |
| Waltham, Massachusetts | 02451 | |
| (Address of principal executive<br> offices) | (Zip Code) |
Registrant’s
telephone number, including area code: (617) 868-1700
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications<br> pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant<br> to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications<br> pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications<br> pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Class<br> A common stock, par value $0.0001 per share | RBOT | The New York Stock Exchange |
| Warrants to purchase one<br> share of Class A common stock, each at an exercise price of $11.50 per share | RBOT WS | The New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item7.01 Regulation FD Disclosure.
On October 13, 2022, Vicarious Surgical Inc. (the “Company”) issued a press release announcing that the Company will host a Demonstration Day of its Beta 2 surgical robot prototype for investors and analysts starting at 11:00 a.m. ET on Tuesday, December 6, 2022, at its Waltham, MA headquarters. Further details will be released closer to the event. Due to limited capacity, in-person attendance is by invitation only. The event will be broadcast live over the internet and will be accessible on the investor relations section of the Company’s website, https://investor.vicarioussurgical.com. A copy of the press release is furnished as Exhibit 99.1 hereto.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release dated October 13, 2022 |
| 104 | Cover Page Interactive Data<br> File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VICARIOUS SURGICAL INC. | ||
|---|---|---|
| By: | /s/<br> Adam Sachs | |
| Name: | Adam Sachs | |
| Title: | President and Chief Executive Officer | |
| Date: October 13,<br> 2022 |
2
Exhibit 99.1
VicariousSurgical Announces Upcoming Beta 2 Demonstration Day
Waltham,Mass., October 13, 2022 – Vicarious Surgical, Inc. (“Vicarious Surgical” or the “Company”), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced that it will host a Demonstration Day of its Beta 2 surgical robot prototype for investors and analysts starting at 11:00 a.m. ET on Tuesday, December 6, 2022, at its Waltham, MA headquarters. Further details will be released closer to the event.
Due to limited capacity, in-person attendance is by invitation only. The event will be broadcast live over the internet and will be accessible on the investor relations section of the Company’s website, https://investor.vicarioussurgical.com.
About Vicarious SurgicalFounded in 2014, Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goals of increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.
Media InquiriesAbby Mayo for Matter Health
media@vicarioussurgical.com
Investor ContactKaitlyn Brosco
Vicarious Surgical
Kbrosco@vicarioussurgical.com
Marissa Bych
Gilmartin Group
Marissa@gilmartinir.com
Source: Vicarious Surgical Inc.